AnnettLevi9: put up basic entry v1

2026-03-19T20:51:45Z

put up basic entry v1

New page

{{Orphan|date=October 2025}}
{{Infobox scientist
| name = Mirza Saqib Baig
| image = Mirza_12-24-2025.tif
| caption = Prof. Baig in 2025
| fields = [[Inflammation]], [[Cancer research]], [[Macrophage]], [[Stem cell]], [[Immunology]], [[Drug development]]
| workplaces = CSIR - [[Indian Institute of Toxicology Research]] (2009-2010)
[[University of Illinois at Chicago]] (2010-2014)
[[Mayo Clinic]] (2014-2015)
[[IIT Indore]] - Indian Institute of Technology Indore (2015-present)
| alma_mater = [[University of Rajasthan]] [[Bachelor of Science|(B.Sc.)]]
[[Aligarh Muslim University]] [[Master of Science|(M.Sc.)]]
[[Central Drug Research Institute]] [[Master of Science|(Ph.D.)]]
| known_for = Innate immunity and inflammatory pathways; TIRAP signaling in cancer and immunity; Onco-immunology; Macrophage biology; Stem cell–immune system interactions; Infectious disease immunology; Therapeutic development
| website = https://msblab.in/
}}

'''Mirza Saqib Baig''' is an Indian researcher, who specializes in [[Systemic inflammation|Chronic Inflammation]] and Cancer Biology.<ref>[https://scholar.google.com/citations?user=bV3oePcAAAAJ&hl=en Mirza Saqib Baig - Google Scholar]</ref> Since 2006, he has published numerous research articles, with the most notable contributions appearing in academic journals such as [[The Journal of Experimental Biology]],<ref name=":0">[[doi:10.1084/jem.20140990|Baig M.S., Zaichick S.V., Mao M., de Abreu A.L., Bakhshi F.R., Hart P.C., Saqib U., Deng J., Chatterjee S., Block M.L., Vogel S.M., Malik A.B., Consolaro M.E., Christman J.W., Minshall R.D., Gantner B.N., Bonini M.G. (2015). NOS1-derived nitric oxide promotes NF-κB transcriptional activity through inhibition of suppressor of cytokine signaling-1. ''Journal of Experimental Medicine'', 212(10), 1725–1738.]]</ref> [[Frontiers Media|Frontiers in Immunology]],<ref>[[doi:10.3389/fimmu.2024.1355012|Baig M.S., Barmpoutsi S., Bharti S., Weigert A., Hirani N., Atre R., Khabiya R., Sharma R., Sarup S., Savai R. (2024). Adaptor molecule mediated negative regulation of macrophage inflammatory pathways: A closer look. ''Frontiers in Immunology'', 15, 1355012.]]</ref><ref>[[doi:10.3389/fimmu.2023.1241440|Baig M.S., Thurston T., Sharma R., Atre R., Saqib U., Khabiya R., Bharti S., Poh C.L. (2023). Targeting signalling pathways in inflammatory diseases. ''Frontiers in Immunology'', 14, 1241440.]]</ref> [[European Journal of Pharmacology]],<ref>[[doi:10.1016/j.ejphar.2024.177160.|Atre R., Obukhov A.G., Majmudar C.Y., Nair K., White F.A., Sharma R., Siddiqi F., Faisal S.M., Verma V.P., Hassan M.I., Mohammad T., Darwhekar G.N., Baig M.S. (2024). Dorzolamide intermediates with potential anti-inflammatory activity. ''European Journal of Pharmacology'', 987, 177160.]]</ref> [[Scientific Reports]],<ref>[[doi:10.1038/s41598-022-09607-5|Rajpoot S., Kumar A., Zhang K.Y.J., Gan S.H., Baig M.S. (2022). TIRAP-mediated activation of p38 MAPK in inflammatory signaling. ''Scientific Reports'', 12(1), 5601.]]</ref><ref>[[doi:10.1038/s41598-018-30782-4|Baig M.S., Roy A., Rajpoot S., Liu D., Savai R., Banerjee S., Kawada M., Faisal S.M., Saluja R., Saqib U., Ohishi T., Wary K.K. (2018). Repurposing thioridazine (TDZ) as an anti-inflammatory agent. ''Scientific Reports'', 8, 12471.]]</ref><ref>[[doi:10.1038/srep39530|Faisal S.M., Varma V.P., Subathra M., Azam S., Sunkara A.K., Akif M., Baig M.S., Chang Y.F. (2016). Leptospira surface adhesin (Lsa21) induces Toll-like receptor 2 and 4 mediated inflammatory responses in macrophages. ''Scientific Reports'', 6, 39530.]]</ref> [[Inflammation Research]]<ref>[[doi:10.1007/s00011-016-1015-0|Srivastava M., Saqib U., Naim A., Roy A., Liu D., Bhatnagar D., Ravinder R., Baig M.S. (2017). The TLR4–NOS1–AP1 signaling axis regulates macrophage polarization. ''Inflammation Research'', 66(4), 323–334.]]</ref><ref>[[doi:10.1007/s00011-024-01921-5|Raizada S., Obukhov A.G., Bharti S., Wadhonkar K., Baig M.S. (2024). Pharmacological targeting of adaptor proteins in chronic inflammation. ''Inflammation Research''.]]</ref> and Inflammopharmacology.<ref>[[doi:10.1007/s10787-025-01675-3|Sarup S., Atre R., Obukhov A.G., Tabrez S., Yadav P., Kshatri A.S., Sk M.H., Baig M.S., ''et al.'' (2025). A thioridazine-derived molecule exhibits potential anti-inflammatory activity through IKK inhibition. ''Inflammopharmacology'', 1–13]]</ref> Baig's research trajectory began with a focus on [[infectious diseases]] and [[immune response]]s, particularly the molecular pathways underlying [[chronic inflammatory]] conditions. He later expanded into [[oncology]], elucidating how immune mechanisms influence [[cancer initiation]], progression, and the [[Tumor microenvironment|tumour microenvironment]]. His current work integrates [[stem cell biology]] with immunological principles to unravel the interactions between stem cells, immune signalling networks, and [[tissue regeneration]], with the overarching goal of developing innovative therapeutic strategies for both cancer and infectious diseases.

== Education ==

Baig obtained his [[Bachelor of Science]] ([[B.Sc]].) degree in 1999 from the [[University of Rajasthan]] (Jaipur, India), followed by a [[Master of Science|Master of Science (M.Sc.)]] in [[Biotechnology]] in 2001 from [[Aligarh Muslim University]] (Aligarh, India). He then pursued doctoral studies in [[Biochemistry]] at the [[Central Drug Research Institute]] (Lucknow, India), earning his Ph.D. in 2008. Subsequently, Baig undertook fellowships in [[inflammation]] and [[cancer research]] at the [[Indian Institute of Toxicology Research]] (Lucknow, India), the [[University of Illinois Chicago|University of Illinois at Chicago]] (Chicago, USA), and the [[Mayo Clinic]] (Rochester, USA).<ref>[[doi:10.1007/s10822-009-9315-y|2. Baig M.S., Kumar A., Siddiqi M.I., Goyal N. (2010). Characterization of dipeptidylcarboxypeptidase of Leishmania donovani: a molecular model for structure-based design of antileishmanials. Journal of Computer-Aided Molecular Design, 24(1), 77–87.]]</ref>

== Career ==

Baig began his research career in 2002 at the [[Central Drug Research Institute]] (Lucknow, India), where he pursued his doctoral studies on the infectious disease and [[Antileishmanial|anti-leishmanial]] drug discovery.<ref>[https://ashpublications.org/blood/article/116/21/827/70063/Valproic-Acid-Results-In-Maintenance-but-Not Araki H., Baluchamy S., Petro B., Baig M.S., Suhangul M., Quigley J.G., et al. (2010). Valproic acid results in maintenance but not expansion of transplantable hematopoietic stem cells from human umbilical cord blood. ''Blood'', 116(21), 827.]</ref><ref name=":2"/> He earned his [[Ph.D]]. in 2008 and subsequently worked at the [[Indian Institute of Toxicology Research]] (Lucknow, India) on Molecular [[Toxicology]].

In January 2010, he joined the [[University of Illinois Chicago|University of Illinois at Chicago]] (Chicago, United States) as a [[postdoctoral researcher]], studying [[hematopoietic stem cell]]s, [[macrophage]]s, and [[endothelial cells]] with a focus on [[chronic inflammation]] and [[cancer]] where he worked with Dr. Nadim Mahmud and Dr. Marcelo Bonini on projects in cancer biology and [[chronic inflammatory]] diseases.<ref name=":1">[https://www.researchgate.net/publication/336490386_Valproic_Acid_Results_In_Maintenance_but_Not_Expansion_of_Transplantable_Hematopoietic_Stem_Cells_From_Human_Umbilical_Cord_Blood Araki H., Baluchamy S., Petro B., Baig M.S., Suhangul M., Quigley J.G., et al. (2010). Valproic acid results in maintenance but not expansion of transplantable hematopoietic stem cells from human umbilical cord blood. ''Blood'', 116(21), 827.]</ref><ref name=":0" /> In 2014, Baig joined the [[Mayo Clinic]] (Rochester, United States) on a [[research fellowship]], where he worked with Dr. Vijay Shah on project related to [[inflammation]] and [[liver fibrosis]].<ref name=":2">[[doi:10.1016/j.lfs.2016.04.031|Baig M.S., Yaqoob U., Cao S., Saqib U., Shah V.H. (2016). Non-canonical role of matrix metalloprotease (MMP) in activation and migration of hepatic stellate cells (HSCs). ''Life Sciences'', 155, 13–21.]]</ref>

In 2015, he returned to India on a fellowship award from the Government of India (Ramalingaswami and Ramanujan Fellowship) and joined the [[Indian Institute of Technology Indore]]. He was appointed [[Assistant professor|Assistant Professor]] in 2016, promoted to [[Associate professor|Associate Professor]] in 2018, and became [[Professor]] in 2023. His laboratory at IIT Indore focuses on understanding the role of macrophages in chronic inflammatory disease and cancer, aiming to identify key therapeutic targets for innovative treatment strategies.

In 2025, Baig received the AHA–International Professorship Award from the [[American Heart Association]], United States.<ref name=":3">{{Cite web |title=MSBLAB |url=https://msblab.in/ |access-date=2026-02-13 |website=msblab.in}}</ref> He was elected a [[Fellow of the Royal Society of Biology]] (RSB) in 2024 and, in the same year, was awarded the Dr. G. P. Talwar Mid-Career Scientist Award by the Indian Immunology Society–Indian Institute of Science (IISc).<ref name=":3" /> His international research appointments include the IUBMB Mid-Career Research Fellowship (2021) from the [[International Union of Biochemistry and Molecular Biology]],<ref>{{Cite web |title=MID CAREER Fellowships awarded 2020 |url=https://iubmb.org/wp-content/uploads/2021/02/MC_2020.pdf |access-date=19 March 2026 |website=[[International Union of Biochemistry and Molecular Biology]]}}</ref> the ASM–IUSSTF Indo-US Professorship (2021) from the [[American Society for Microbiology]],<ref>[https://iusstf.org/asm-iusstf-indo-us-professorship-in-microbiology ASM-IUSSTF Indo-US Professorship in Microbiology - Iusstf]</ref> and the International Collaborative Research Award (2021) from the [[Japan Agency for Medical Research and Development]] (AMED) and the New York Academy of Sciences (NYAS).<ref name=":3" /> He has also been profiled by the [[New York Academy of Sciences]] and featured on other scientific and media platforms.<ref>{{Cite web |last=Sciences |first=The New York Academy of |date=2025-07-02 |title=Reflections from Academy Member Prof. Mirza S. Baig - NYAS |url=https://www.nyas.org/ideas-insights/blog/reflections-from-academy-member-prof-baig/ |access-date=2026-02-13 |language=en-US}}</ref><ref>[https://www.nyas.org/ideas-insights/blog/iamnyas-immunologist-mirza-s-baig/ #IAmNYAS: Immunologist Mirza S. Baig - NYAS]</ref><ref>[https://www.newindiakhabar.com/2025/06/12/%E0%A4%9C%E0%A4%AF%E0%A4%AA%E0%A5%81%E0%A4%B0-%E0%A4%95%E0%A4%BE-%E0%A4%85%E0%A4%A4%E0%A5%81%E0%A4%B2%E0%A4%A8%E0%A5%80%E0%A4%AF-%E0%A4%B0%E0%A4%A4%E0%A5%8D%E0%A4%A8-%E0%A4%AA%E0%A5%8D%E0%A4%B0/ जयपुर का अतुलनीय रत्न, प्रो. (डॉ.) मिर्ज़ा साक़िब बैग, बायोमेडिकल विज्ञान में वैश्विक योगदान के लिए हार्वर्ड में सम्मानित,, - Newindiakhabar]</ref><ref>[https://www.freepressjournal.in/education/fpj-ed-nobel-laureate-david-julius-says-india-has-lot-of-scientific-potentials FPJ-Ed: Nobel Laureate David Julius says India has lot of scientific potentials]</ref>
Baig has been invited to deliver lectures and collaborate with leading institutions worldwide.<ref name=":3" /> His engagements include visits to [[Harvard University]], [[Tufts University]], [[Rutgers University]], and [[Indiana University School of Medicine]] in the United States; [[University of Cambridge]], [[University of Oxford]], and [[King's College London]] in the United Kingdom; the [[University of California, San Francisco|University of California San Francisco]] and the [[University of Illinois Chicago|University of Illinois at Chicago]] in the United States; Technical University of Munich in Germany; [[Tohoku University]] and [[University of Osaka|Osaka University]] in Japan; [[Koç University|Koc University]] and [[Middle East Technical University]] in Turkey; and [[Sapienza University of Rome|Sapienza University]] of Rome in Italy.
[[File:Prof. Baig at the University of Queensland in 2025.jpg|thumb|Prof. Baig at the University of Queensland in 2025]]
[[File:Mirza Australia 2025.tif|thumb|Prof. Baig with Mr. Ananth and Prof. Bob Graham in 2025]]

=== Academic Visit to the University of Queensland, Australia ===
Under the Indian Council of Medical Research Visiting Professorship Program, Prof. Baig visited [[University of Queensland|the University of Queensland]] in Brisbane in 2025 to foster Indo–Australian collaborations in the fields of [[chronic inflammation]] and [[cancer research]]. During his visit, he delivered lectures at multiple Australian universities and engaged with Infensa Bioscience on translational drug discovery initiatives. Prof. Baig has also been honored and profiled by the Australian Science Media Centre Inc (Mirza Saqib Baig - Scimex).
== Teaching ==
Baig teaches [[Immunology]], [[Biochemistry]], [[Cell biology|Cellular]] and [[Molecular biology|Molecular Biology]], [[Drug discovery|Drug Discovery]] & Development at the [[Indian Institutes of Technology|Indian Institute of Technology]] in Indore.<ref>{{Cite web |title=IIT Indore, भारतीय प्रौद्योगिकी संस्थान इंदौर |url=http://www.iiti.ac.in/ |access-date=2026-02-13 |website=IIT Indore |language=en}}</ref>

== Professional affiliations ==
Prof. Baig is a professional member of several national and international scientific organizations, including the European Association for Cancer Research, [[American Society for Microbiology]], [[Indian Science Congress Association]], [[New York Academy of Sciences]], [[American Heart Association]], British Society for Cell Biology, and [[British Society for Antimicrobial Chemotherapy]].<ref name=":1" />

== References ==
{{Reflist}}

{{DEFAULTSORT:Baig, Mirza Saqib}}
[[Category:Living people]]
[[Category:University of Rajasthan alumni]]
[[Category:Aligarh Muslim University alumni]]
[[Category:21st-century Indian educators]]
[[Category:Year of birth missing (living people)]]

Mirza Saqib Baig - Revision history

AnnettLevi9: put up basic entry v1